Dotmatics

Life Sciences: The State of Data Integrity and Security

The Pharma IQ report, in collaboration with Dotmatics and BioBright, emphasizes the critical importance of data integrity, security, and encryption throughout the drug product lifecycle in life sciences, highlighting strategies such as automation and regulatory compliance to drive digital transformation and secure analytics in pharmaceutical research and development.

Ensuring Data Integrity, Security, and Encryption in Life Sciences

To ensure the safety, quality, and efficacy of a drug product prior to market roll out, it is critical that life sciences companies uphold the integrity and security of the data generated throughout an entire product’s lifecycle.

While advances in technology have propelled the life sciences industry forward, driving organizations to be data compliant will accelerate the use of secure analytics applications. This, in turn, fuels the digital economy in pharma and helps companies avoid risky outcomes.

Pharma IQ’s report, in collaboration with Dotmatics and BioBright, explores why pharmaceutical data integrity and data security are more important than ever in the life sciences industry.

“At the most macro level, there has been a race by every actor in biological research and clinical development to digitize information and to make analytics at scale possible.”

Charles Fracchia, CEO of BioBright & VP of Data at Dotmatics

Key Insights from the Report

  • Strategies for data integrity and data security to enhance the digitization of the life sciences industry.
  • How to improve data integrity and data security through automation.
  • Approaches to overcoming regulatory challenges in digital transformation.
  • Driving digital change in pharma business models by putting data security, data integrity, and encryption at the core of your data strategy.